Unknown Effects of China Retaliation Cloud Illumina's 2025 Expectations After 2024 Revenue Decline
Premium
Fourth quarter sales in China were up 1 percent, as Illumina beat Wall Street estimates on the top and bottom lines.

Malaria Parasite Adaptations Identified in Mutagenesis Studies
Essential genome analyses done with mutagenesis screening have uncovered apparent genes involved in drug resistance and species-specific adaptations.
Long Read-Based Fiber-seq Chromatin Accessibility Method Draws Academic, Commercial Interest
Premium
The method, which adds chromatin accessibility information to long-read whole-genome sequencing, is gaining momentum as more labs seek to implement it.
Assaying both CTCs and ctDNA simultaneously offers a path to more accurate and early cancer detection and drug response monitoring.
Becton Dickinson to Spin Off Biosciences and Diagnostics Business as Q1 Revenues Grow 10 Percent
Premium
The separation is planned to be completed by the end of 2026 with the rest of the company transforming into a pure play medical technology firm.
Qiagen Q4 Revenues Rise 2 Percent, Exceed Guidance, Analyst Estimates
The firm also said it has reorganized its global business into a products-focused unit and a sales and marketing unit.
CZI, 10x Genomics, Ultima Genomics to Sequence 1 Billion Single Cells to Train AI Models
The project is also partnering with academic researchers, including Alexander Marson, director of the Gladstone-UCSF Institute of Genomic Immunology.
Companies on the list are subject to a series of sanctions, including import and export control restrictions, barred business activities in China, and fines.